Liminal BioSciences Reports First Quarter Financial Results 2023

GPR84 antagonist program and OXER1 antagonist program on track to meet previously stated milestones in 2023Closed March 31, 2023 with just over CAD26.9 million cash on hand, expecting to provide... | June 16, 2023

Related Keywords

United Kingdom ,Canada ,Cambridge ,Cambridgeshire ,Canadian ,Bruce Pritchard ,Liminal Biosciences Inc ,Exchange Commission ,Nasdaq ,Contract Development Manufacturing Organization ,Securities Exchange ,Chief Executive Officer ,Quarter Ended March ,Contract Development Manufacturing ,Securities Act ,Securities Exchange Act ,Liminal Bioscience ,Nasdaq Listing Rule ,Nasdaq Capital Market ,Canadian Securities Administrators ,Annual Report ,